"The interim results demonstrated a highly differentiated clinical profile for TUB-040 in the ADC field, with anti-tumor activity beginning at low doses with a broad therapeutic window that could ...

TUB-040 demonstrated robust clinical activity with a favorable safety profile and excellent tolerability in biomarker-unselected, heavily pre-treated PROC patients At data-cut-off on September 1, 2025 ...

Liz Simmons is an education staff writer at Forbes Advisor. She has written about higher education and career development for various online publications since 2016. She earned a master’s degree in ...

A startup called Ardent AI Labs Inc. says data engineering is the next major discipline in line for “agentic” automation after getting $2.15 million in a pre-seed funding round. The money comes from ...

Community driven content discussing all aspects of software development from DevOps to design patterns. The Google Cloud Data Associate certification confirms your ability to work with Google Cloud’s ...

Community driven content discussing all aspects of software development from DevOps to design patterns. The Google Cloud Data Practitioner Associate certification validates your ability to manage, ...

ARCHBALD, Pa. — Carolyn Mizanty walks at Ed Staback Park in Archbald every day her view may soon drastically change if the borough approves a pair of projects to build data centers, "I think it ...

Corcept Therapeutics Incorporated's relacorilant met the primary endpoint in the phase 3 ROSELLA study for platinum-resistant ovarian cancer patients, boosting shares by over 90% the very same day.

(RTTNews) - Zentalis Pharmaceuticals Inc. (ZNTL) announced updated clinical data from Part 1b of the ongoing DENALI clinical trial of azenosertib in patients with platinum-resistant ovarian cancer or ...

(RTTNews) - AbbVie (ABBV) announced that final data analysis from Phase 3 MIRASOL trial after 30.5-month median follow-up demonstrated 32% reduction in risk of death with ELAHERE or mirvetuximab ...